Esophageal Squamous Cell Carcinoma
Therapeutic response
Precision oncology relationships for therapeutic response involving this cancer type.
| Type | Biomarker(s) | Cancer type | Therapy(ies) | |
|---|---|---|---|---|
| Sensitivity (+) | PD-L1 >= 1% | Esophageal Squamous Cell Carcinoma | Ipilimumab, Nivolumab | |
| Sensitivity (+) | PD-L1 >= 1% | Esophageal Squamous Cell Carcinoma | Cisplatin, Fluorouracil, Nivolumab | |
| Sensitivity (+) | PD-L1 >= 1% | Esophageal Squamous Cell Carcinoma | Ipilimumab, Nivolumab | |
| Sensitivity (+) | PD-L1 (TAP) >= 5% | Esophageal Squamous Cell Carcinoma | Cisplatin, Fluorouracil, Tislelizumab | |
| Sensitivity (+) | PD-L1 (TAP) >= 5% | Esophageal Squamous Cell Carcinoma | Capecitabine, Cisplatin, Tislelizumab | |
| Sensitivity (+) | PD-L1 (TAP) >= 5% | Esophageal Squamous Cell Carcinoma | Fluorouracil, Oxaliplatin, Tislelizumab | |
| Sensitivity (+) | PD-L1 (TAP) >= 5% | Esophageal Squamous Cell Carcinoma | Capecitabine, Oxaliplatin, Tislelizumab | |
| Sensitivity (+) | PD-L1 (TAP) >= 5% | Esophageal Squamous Cell Carcinoma | Cisplatin, Paclitaxel, Tislelizumab | |
| Sensitivity (+) | PD-L1 (TAP) >= 5% | Esophageal Squamous Cell Carcinoma | Oxaliplatin, Paclitaxel, Tislelizumab |